Evidence map›Paper›PMID 42036046›Full record

ArticleThe Journal of biological chemistry2026

Profiling of fatty acids and lipids in animal and human tissues yields new leads for disease progression biomarkers of X-linked adrenoleukodystrophy.

Alla Kloss, Laura Parisi, Donghui Wang, Martin Hanus, Rachelle Golden, Kelly Keefe, Ruby Chiang, Yihang Li, Alex Brezzani, Paul Lang and 2 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Lipid signature in X-ALD: a comparison between phenotypes.Frontiers in molecular biosciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alla KlossSanofi, US Early Development, CMC, Cambridge, Massachusetts, USA. Electronic address: allakloss.w@gmail.com.
Laura ParisiSanofi, US Early Development, CMC, Cambridge, Massachusetts, USA.
Donghui WangSanofi, US Early Development, CMC, Cambridge, Massachusetts, USA.
Martin HanusSanofi, US Early Development, CMC, Cambridge, Massachusetts, USA.
Rachelle GoldenSanofi, US Early Development, CMC, Cambridge, Massachusetts, USA.
Kelly KeefeSanofi, Rare and Neurologic Diseases, Cambridge, Massachusetts, USA.
Ruby ChiangSanofi, Rare and Neurologic Diseases, Cambridge, Massachusetts, USA.
Yihang LiSanofi, Rare and Neurologic Diseases, Cambridge, Massachusetts, USA.
Alex BrezzaniSanofi, Rare and Neurologic Diseases, Cambridge, Massachusetts, USA.
Paul LangSanofi, In Vitro Biology US Integrated Drug Discovery, Cambridge, Massachusetts, USA.
Can KayatekinSanofi, Rare and Neurologic Diseases, Cambridge, Massachusetts, USA.
Tatiana GladyshevaSanofi, In Vitro Biology US Integrated Drug Discovery, Cambridge, Massachusetts, USA. Electronic address: tatiana.gladysheva@sanofi.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-ALD is a rare disorder caused by impaired β-oxidation of very long-chain fatty acids, their accumulation, and incorporation in lipids, resulting in pathology, severely impacting the central nervous system. Thorough comparative profiling of fatty acids and lipids in different human tissues and biological fluids described in this manuscript has revealed significant differences in composition, which explained why blood lipids successfully used as diagnostics biomarkers for X-ALD do not correlate with disease progression and cannot inform decision-making regarding medical intervention. Our data yielded insights into understanding why the metabolic disorder resulting in elevated levels of VLCFAs in all tissues in X-ALD patients causes severe pathology limited to the central nervous system. We then conducted global lipid profiling of cerebrospinal fluid from pediatric patients and, using data filtering based on disease progression trend, identified new leads for lipid markers with strong disease progression correlations. Data suggests that a few associated proteins should be evaluated as potential biomarkers that may be detectable in blood. We also present data from lipids and fatty acids profiling of tissues from the X-ALD mouse model and WT mice, and comparison with the profiling data obtained for human tissues. This analysis yielded clues to understanding why the ABCD1 KO mouse model, which has the relevant biochemical phenotype, develops only a subtle pathology, while in humans, disease manifestation is severe. In the ABCD1 KO mouse longitudinal study reported in this manuscript, we have identified trending lipids that may serve as sensitive biomarkers of fatty acid metabolism modulations.

Indexed as

AdrenoleukodystrophyDisease ProgressionFatty AcidsLipidsAnimalsATP Binding Cassette Transporter, Subfamily D, Member 1BiomarkersChildDisease Models, AnimalFemaleHumansMaleMiceMice, KnockoutATP Binding Cassette Transporter, Subfamily D, Member 1BiomarkersFatty AcidsLipidsABCD1 knockout mouse modeladrenoleukodystrophy proteinadrenomyeloneuropathybiomarkerscentral nervous systemcerebral adrenoleukodystrophydemyelinationELOVL1fatty acidsgas chromatrography-triple quadrupole mass spectrometrylipidomicslipidsliquid chromatography-mass spectrometryvery long chain fatty acidsX-linked adrenoleukodystrophy,

Identifiers

PMID42036046
PMCPMC13234235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.